Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 142 of 144 pages ‹ First < 140 141 142 143 144 >
HSL20096
Mold F
Caution urged over drug advertising
MediaSearch 2000 Jun 23
HSL20098
Simpson M
Report on controversial drug stand attracts global interest
The National Business Review 2000 Jun 23
HSL20136
Moynihan R
NZ to get tough on drug ads
The Australian Financial Review 2000 Jun 23
HSL2576
Wilmshurst P.
Academia and industry (1st of 2 letters)
The Lancet 2000 Jun 22; 356:338-339
HSL18015
Angell M.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Jun 22; 342:(25):1902-4
http://content.nejm.org/cgi/content/extract/342/25/1902
HSL20092
Pill scare 'shows dangers' of ads
New Zealand Press Association 2000 Jun 22
HSL20095
Pill scare shows advertising risk, says Pharmac
The Evening Post 2000 Jun 22
HSL20101
Drug promotion risks highlighted
West Coast Times 2000 Jun 22
HSL20111
Moynihan R
Glaxo defends flu campaign
The Australian Financial Review 2000 Jun 20
HSL2605
O'Hare N.
Pill pushers
Listener 2000 Jun 1719-23
HSL7934
Texas fight over drug product selection ends
American Journal of Health System Pharmacy 2000 Jun 15; 57:1117
HSL7945
Chisholm MA, Reinhardt BO, Vollenweider LJ, Kendrick BD, DiPiro JT.
Medication assistance programs for uninsured and indigent patients.
Am J Health Syst Pharm 2000 Jun 15; 57:(12):1131-6
http://www.ajhp.org/cgi/reprint/57/12/1131
HSL207
Tallon D, Chard J, Dieppe P.
Relation between agendas of the research community and the research consumer.
Lancet 2000 Jun 10; 355:(9220):2037-40
http://linkinghub.elsevier.com/retrieve/pii/S0140673600023515
HSL7884
Aitken M, Holt F.
Consumer choice or chaos?
Chemist and Druggist 2000 Jun 10; 253:34, 36
HSL8947
Balasubramaniam T
Background Information on Fourteen FDA Approved HIV/AIDS Drugs
Washington, DC: Consumer Project on Technology 2000 Jun 8
http://www.cptech.org/ip/health/aids/druginfo.html
HSL216
Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, Mah C, Soumerai SB.
Coverage by the news media of the benefits and risks of medications.
N Engl J Med 2000 Jun 1; 342:(22):1645-50
http://content.nejm.org/cgi/content/full/342/22/1645
HSL230
Chard JA, Tallon D, Dieppe P.
Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint
Annals of the Rheumatic Diseases 2000 Jun; 59:414-418
http://ard.bmjjournals.com/cgi/content/full/59/6/414
HSL1856
Mehta PN.
Drugmakers and continuing medical education.
Indian Pediatr 2000 Jun; 37:(6):626-30
HSL3703
Researched Medicines Industry (RMI).
Direct to consumer advertising can enhance public health. The case for direct-to-consumer prescription medicine advertising.
Wellington NZ: Researched Medicines Industry (RMI). 2000 Jun
HSL4601
D'Arcy PF, Hadden DR.
Are drug proprietary names necessary?
Adverse Drug React Toxicol Rev 2000 Jun; 19:(2):117-21
HSL1686
Wazana A.
Gifts to physicians from the pharmaceutical industry
JAMA 2000 May 24; 283:(20):2655-8
HSL2579
Wazana A.
Gifts to physicians from the pharmaceutical industry [1st of 2 replies]
JAMA 2000 May 24-31; 283:(20):2675
HSL2631
McKinney WP.
Gifts to physicians from the pharmaceutical industry [4th of 4 letters]
JAMA 2000 May 24-31; 283:(20):2656-7
HSL6938
Edwards DA.
Gifts to physicians from the pharmaceutical industry.
JAMA 2000 May 24-31; 283:(20):2656
HSL6939
Howard SM.
Gifts to physicians from the pharmaceutical industry.
JAMA 2000 May 24-31; 283:(20):2655-6
HSL6940
McKinney WP, Rich EC.
Gifts to physicians from the pharmaceutical industry.
JAMA 2000 May 24-31; 283:(20):2656-7
HSL6941
Vollman J.
Gifts to physicians from the pharmaceutical industry [3rd of 4 letters]
JAMA 2000 May 24-31; 283:(20):2656
HSL231
Bodenheimer T.
Uneasy alliance--clinical investigators and the pharmaceutical industry.
N Engl J Med 2000 May 18; 342:(20):1539-44
http://content.nejm.org/cgi/content/extract/342/20/1539
HSL234
Angell M.
Is academic medicine for sale?
N Engl J Med 2000 May 18; 342:(20):1516-8
http://content.nejm.org/cgi/content/extract/342/20/1516
HSL8949
Office of the Chairman
The Benefits of Medical Research and the Role of the NIH
Washington, DC: US Senate 2000 May 17
http://hsc.utoledo.edu/research/nih_research_benefits.pdf
HSL856
Irwig LM, Loy CT, Chapman S, Glasziou PP, Mansfield PR, Salkeld GP, Walton MM.
!nform test kits distributed with the MJA.
Med J Aust 2000 May 15; 172:(10):518-9
HSL7917
Starr CH.
When drug names spell trouble
Drug Topics 2000 May 15; 144:49-50, 53-54, 57-58
HSL6937
MacKay P.
Pharmaceutical advertising - as seen on TV
New Zealand Association Newsletter 2000 May 121-2
HSL20159
Older consumers missing fine print in direct-to-consumer drug ads
Reuters Medical News 2000 May 12
HSL20113
MacKinven M
Drug makers risking penalties over promos
New Zealand Doctor 2000 May 1015
HSL2578
Weatherall D.
Academia and industry: increasingly uneasy bedfellows.
Lancet 2000 May 6; 355:(9215):1574
http://linkinghub.elsevier.com/retrieve/pii/S014067360002211X
HSL20137
Moodie P
Feeling blue? Have we got the drug for you!
New Zealand GP 2000 May 310
HSL2285
Sackett DL.
Why randomized controlled trials fail but needn't: 1. Failure to gain "coal-face" commitment and to use the uncertainty principle.
CMAJ 2000 May 2; 162:(9):1311-4
http://www.cmaj.ca/cgi/content/full/162/9/1311
HSL7947
Swartwood DE.
Ethics and managed care formularies.
Am J Health Syst Pharm 2000 May 1; 57:(9):851
http://www.ajhp.org/
HSL7952
McAllister JC.
Fortresses and formularies: response 3
American Journal of Health System Pharmacy 2000 May 1; 57:859-860
HSL6936
Kollek D.
How advertisements have changed
Canadian Family Physician 2000 May; 46:1025-1026
HSL7822
Cooper W.
Drug wars, episode two: health plans strike back
Pharmaceutical Executive 2000 May; 110, 112, 114
HSL7826
Wechsler J.
Congressional concerns
Pharmaceutical Executive 2000 May; 20:22, 24, 26, 28
HSL7851
Smeaton J.
To market, to market
Australian Journal of Pharmacy 2000 May; 81:470-471
HSL19542
Pomper S
Drug Rush: Why the Prescription Drug Market is Unsafe at High Speeds
Washington Monthly 2000 May
http://www.washingtonmonthly.com/features/2000/0005.pomper.html
HSL20139
Jeffries M
The mark of Zorro
Pharmaceutical Marketing 2000 May;
HSL18016
Mann RD, Pearce GL, Dunn N, Shakir S.
Sedation with 'non-sedating' antihistamines: four prescription-event monitoring studies in general practice - Commentary: Reporting of adverse events is worth the effort
BMJ 2000 Apr 29; 320:(7243):1184-6
http://www.bmj.com/cgi/content/full/320/7243/1184?view=long&pmid=10784544
HSL19543
Gerth J, Stolberg SG
Drug Companies Profit From Research Supported by Taxpayers
The New York Times 2000 Apr 23
http://partners.nytimes.com/library/national/science/health/042300hth-drugs.html
HSL19544
Mullins CD, Palumbo F, Stuart B,
The Impact of Pipeline Drugs on Pharmaceutical Spending
Center on Drugs and Public Policy University of Maryland School of Pharmacy 2000 Apr 13
www.ahipresearch.org/PDFs/25_ExecSumImpactofPipelineDrugs.pdf
HSL19545
Henney J
The Drug Industry’s Performance In Finishing Postmarketing Research (Phase IV) Studies
Public Citizen 2000 Apr 13
http://www.citizen.org/hrg1520
HSL7931
Gebhart F.
They shoot! They score! Rx scoreboard
Drug Topics 2000 Apr 3; 144:31-32, 35-36, 39
HSL5303
Medical Research Council
A framework for development and evaluation of RCTs for complex interventions to improve health
: Medical Research Council 2000 Apr 1
http://www.mrc.ac.uk/prn/pdf-mrc_cpr.pdf
HSL2588
Sarmiento A.
Medicine and industry: The payer, the piper, and the tune
Annales CRMCC 2000 Apr; 33:(3):144-149
HSL3705
Bell RA, Kravitz RL, Wilkes MS.
Direct-to-consumer prescription drug advertising, 1989-1998. A content analysis of conditions, targets, inducements, and appeals.
J Fam Pract 2000 Apr; 49:(4):329-35
http://www.jfponline.com/Pages.asp?AID=2488
HSL6935
Barros JA.
[(Mis)information on drugs: the double standard practiced by pharmaceutical companies]
Cad Saude Publica. 2000 Apr-Jun; 16:(2):421-7
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2000000200012&tlng=es&lng=en&nrm=iso
HSL19546
Department of Health & Human Services
Prescription Drug Coverage, Spending, Utilization, and Prices
2000 Apr
http://aspe.hhs.gov/health/reports/drugstudy/
HSL19547
Greene J
Drug Reps Targeting Nonphysicians
American Medical News 2000 Mar 27
http://www.ama-assn.org/amednews/2000/03/27/prl20327.htm
HSL2585
Sharp D.
Drug industry code proposed on "ghost" writing
Lancet 2000 Mar 25; 355:1084
HSL7925
Prescriptions benefits for America's elderly
Lancet 2000 Mar 25; 355:1027
HSL7930
Conlan MF.
Consumers speak out
Drug Topics 2000 Mar 20; 144:71-72, 74, 77-78, 81
HSL179
Willman D.
Fears Grow Over Delay in Removing Rezulin Health: Five FDA physicians say the lives of diabetes patients are at stake. Company's conduct in development of the drug also comes under fire.
The Los Angeles Times 2000 Mar 10
HSL6932
Armstrong K, Asch DA.
Direct sale of sildenafil (Viagra) to consumers over the Internet (3rd of 3 letters)
New England Journal of Medicine 2000 Mar 9; 342:(10):742
HSL6933
deKieffer DE.
Direct sale of sildenafil (Viagra) to consumers over the Internet.
N Engl J Med 2000 Mar 9; 342:(10):742
HSL6934
Henney JE, Shuren JE.
Direct sale of sildenafil (Viagra) to consumers over the Internet.
N Engl J Med 2000 Mar 9; 342:(10):740,
HSL11548
Miller D, Dinan W.
The Rise of the PR Industry in Britain, 1979-98
European Journal of Communication 2000 Mar 1; 15:(1):5-35
http://ejc.sagepub.com/cgi/content/abstract/15/1/5
HSL2604
Press E, Washburn J.
The kept university
Atlantic Monthly 2000 Mar39-42, 44-52, 54
www.theatlantic.com/issues/2000/03/press.htm
HSL6926
Wilkes MS, Bell RA, Kravitz RL.
Direct-to-consumer prescription drug advertising: trends, impact, and implications.
Health Aff (Millwood) 2000 Mar-Apr; 19:(2):110-28
http://content.healthaffairs.org/cgi/reprint/19/2/110
HSL6929
Lexchin J.
Plus ça change.
Canadian Family Physician 2000 Mar; 46:532-6
HSL6930
Lexchin J.
Re: the promotion of Augmentin (amoxycillin/clavulanate)
2000 Mar;
HSL7893
Edlin M.
Health plans rein in formulary costs
Managed Healthcare 2000 Mar; 10:30-32, 48
HSL18012
Rettig RA.
The industrialization of clinical research.
Health Aff (Millwood) 2000 Mar-Apr; 19:(2):129-46
http://content.healthaffairs.org/cgi/reprint/19/2/129
HSL18014
Falkenberg T, Tomson G.
The World Bank and pharmaceuticals.
Health Policy Plan 2000 Mar; 15:(1):52-8
http://heapol.oxfordjournals.org/cgi/reprint/15/1/52?view=long&pmid=10731235
HSL224
Jadad AR, Moher M, Browman GP, Booker L, Sigouin C, Fuentes M, Stevens R.
Systematic reviews and meta-analyses on treatment of asthma: critical evaluation.
BMJ 2000 Feb 26; 320:(7234):537-40
http://bmj.bmjjournals.com/cgi/content/full/320/7234/537
HSL6928
Angell M, Utiger RD, Wood AJ.
Disclosure of authors' conflicts of interest: a follow-up.
N Engl J Med 2000 Feb 24; 342:(8):586-7
HSL8948
Consumer Project on Technology
Additional notes on government role in the development of HIV/AIDS drugs
Washington, DC: Consumer Project on Technology 2000 Feb 23
http://www.cptech.org/ip/health/aids/gov-role.html
HSL18010
Anis AH.
Pharmaceutical policies in Canada: another example of federal-provincial discord.
CMAJ 2000 Feb 22; 162:(4):523-6
http://www.cmaj.ca/cgi/content/full/162/4/523
HSL177
Willman D.
Key Physician Urges Rezulin Be Withdrawn Medicine: FDA official says 'preventable liver failure' may occur if diabetes pill remains on market. The number of injuries and deaths linked to drug rises.
The Los Angeles Times 2000 Feb 19
HSL1858
Damur C, Steurer J.
[Do physicians interpret therapy outcome differently than students?]
Schweiz Med Wochenschr 2000 Feb 12; 130:(6):171-6
HSL2090
Hemminki E, McPherson K.
Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease.
Lancet 2000 Feb 12; 355:(9203):566-9
http://linkinghub.elsevier.com/retrieve/pii/S0140673699034327
HSL7943
Levy S.
First DTC drug ads of 2000 promote a wide assortment
Drug Topics 2000 Feb 7; 144:120, 122
HSL7944
Chi J.
Drug budget spiraling out of control? Here's how to rein in your costs
Drug Topics 2000 Feb 7; 144:64
HSL7896
Smeaton J.
Moving pictures
Australian Journal of Pharmacy 2000 Feb; 81:128-129
HSL18011
Carne X, Arnaiz JA.
Methodological and political issues in clinical pharmacology research by the year 2000.
Eur J Clin Pharmacol 2000 Feb-Mar; 55:(11-12):781-5
http://www.ncbi.nlm.nih.gov/pubmed/10805054
HSL6927
Hailey D.
Scientific harassment by pharmaceutical companies: time to stop.
CMAJ 2000 Jan 25; 162:(2):212-3
http://www.cmaj.ca/cgi/content/full/162/2/212 and http://www.cmaj.ca/cgi/content/full/162/2/212
HSL20122
Pharmaceutical companies taken to court for forbidden drug advertising
The Volkskrant 2000 Jan 227
HSL2152
Wazana A.
Physicians and the pharmaceutical industry: is a gift ever just a gift?
JAMA 2000 Jan 19; 283:(3):373-80
http://jama.ama-assn.org/cgi/content/full/283/3/373
HSL2580
Tenery RM Jr.
Interactions between physicians and the health care technology industry.
JAMA 2000 Jan 19; 283:(3):391-3
http://jama.ama-assn.org/cgi/content/full/283/3/391
HSL14719
Zablocki E.
Drug Company Gifts May Affect the Way Doctors Practice Medicine
WebMD 2000 Jan 18
http://www.webmd.com/news/20000118/drug-company-gifts-may-affect-way-doctors-practice-medicine
HSL7956
Gebhart F.
Flush with victory, compounding pharmacists see demand soar
Drug Topics 2000 Jan 17; 144:28, 31
HSL7907
Reissner D.
Pharmacy on the Net: is it legal?
Chemist and Druggist 2000 Jan 15; 253:20
HSL7949
Levy S.
Marketing switch
Drug Topics 2000 Jan 3; 144:36
HSL220
Lovdahl U, Riska E.
The construction of gender and mental health in Nordic psychotropic-drug advertising.
Int J Health Serv 2000; 30:(2):387-406
HSL235
Angell M.
The pharmaceutical industry--to whom is it accountable
N Engl J Med 2000; 342:1902-1904
http://content.nejm.org/cgi/content/extract/342/25/1902
HSL2635
Maestri E, Furlani G, Suzzi F, Campomori A, Formoso G, Magrini N.
So much time for so little: Italy's pharmaceutical industry and doctors' information needs.
BMJ 2000 Jan 1; 320:(7226):55-6
http://bmj.com/cgi/content/full/320/7226/55
HSL2078
Robinson P, Heywood P.
What do GPs need to know? The use of knowledge in general practice consultations.
Br J Gen Pract 2000 Jan; 50:(450):56-9
http://www.ingentaconnect.com/content/rcgp/bjgp/2000/00000050/00000450/art00016?token=00601ae60a99037bb575686f3a576b3427656c3c6a334025757d5c4f7e41225f406a592c494673482825734523ac65ff
HSL7912
Smith DL.
Don't forget about us after the initial DTC ad
Pharmaceutical Executive 2000 Jan; 20:113
HSL7913
West D.
Dialing for DTC: operation 1-800-call center gets the scoop
Pharmaceutical Executive 2000 Jan; 20:98-100, 102, 104, 106
HSL225
Guldal D, Semin S.
The influences of drug companies' advertising programs on physicians
Int J Health Serv 2000; 30:(3):585-95
HSL1496
Cialdini RB.
Influence: Science and Practice 4th Edn
New York: Allyn & Bacon 2000
http://www.ablongman.com/catalog/academic/product/0,1144,0321011473,00.html
HSL1847
Pearson S, Smith AJ, Rolfe IE, Moulds RF, Shenfield GM.
Intern Prescribing for Common Clinical Conditions.
Adv Health Sci Educ Theory Pract 2000; 5:(2):141-150
http://www.springerlink.com/app/home/contribution.asp?wasp=e0f7248c20da438d88ea51c792f37dae&referrer=parent&backto=issue,6,7;journal,16,26;linkingpublicationresults,1:102840,1
Page 142 of 144 pages ‹ First < 140 141 142 143 144 >
